000399266 000__ 03818cam\a22003734a\4500
000399266 001__ 399266
000399266 005__ 20210513141325.0
000399266 006__ m\\\\\\\\u\\\\\\\\
000399266 007__ cr\cn|||||||||
000399266 008__ 010517s2002\\\\ctua\\\\sb\\\\101\0\eng\\
000399266 010__ $$z  2001039022
000399266 020__ $$z0300087519 (cloth : alk. paper)
000399266 035__ $$a(CaPaEBR)ebr10210208
000399266 035__ $$a(OCoLC)648337536
000399266 040__ $$aCaPaEBR$$cCaPaEBR
000399266 05014 $$aRA643.8$$b.Q36 2002eb
000399266 08204 $$a362.1/969792$$221
000399266 24500 $$aQuantitative evaluation of HIV prevention programs$$h[electronic resource] /$$cedited by Edward H. Kaplan and Ron Brookmeyer.
000399266 260__ $$aNew Haven :$$bYale University Press,$$cc2002.
000399266 300__ $$ax, 335 p. :$$bill. ;$$c25 cm.
000399266 4901_ $$aThe Yale ISPS series
000399266 500__ $$aProceedings of a conference sponsored by the Societal Institute of the Mathematical Sciences (the 14th in a series of research application conferences begun in 1974) held in July, 1998, in Divonne-les-Bains, France.
000399266 504__ $$aIncludes bibliographical references and index.
000399266 5058_ $$aMachine generated contents note: Part I: Evaluating HIV Prevention Programs: Context and Concepts -- Chapter 1. Overview of HIV Prevention Programs in Developing Countries Michael H. Merson andJulia M. Dayton 13 -- Chapter 2. Implications of Economic Evaluations for National HIV Prevention Policy Makers David R. Holtgrave -- and Steven D. Pinkerton 32 -- Chapter 3. Statistical Issues in HIV Prevention Ron Brookmeyer 55 -- Chapter 4. Epidemiological Issues in the Evaluation of HIV Prevention Programs Nancy S. Padian and Stephen C. Shiboski 79 -- Part II: Cost-Effectiveness and Resource Allocation -- Chapter 5. Difficult Choices, Urgent Needs: Optimal Investment in HIV Prevention Programs Margaret L. Brandeau 97 Chapter 6. Methadone Treatment as HIV Prevention: Cost-EffectivenessAnalysis Harold Pollack 118 -- Chapter 7. Costs and Benefits of Imperfect HIV Vaccines: Implications for Vaccine Development and Use Douglas K Owens, Donna M. Edwards, and Ross D. Shachter 143 -- Part III: Case Studies -- Chapter 8. Harm Reduction in Rome: A Model-Based Evaluation of Its Impact on the HIV-1 Epidemic MassimoArca, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci 175 -- Chapter 9. Evaluating Israel's Ethiopian Blood Ban EdwardH. Kaplan 189 -- Chapter 10. Feeding Strategies for Children of HIV-Infected Mothers: Modeling the Trade-Off Between HIV Infection and Non-HIV Mortality James G. Kahn, ElliotMarseille, and Joseph Saba 202 -- Part IV: New Methods for New Problems -- Chapter 11. Design of HIVTrials for Estimating External Effects Tomas Philipson 223 -- Chapter 12. Estimation of Vaccine Efficacy for Prophylactic HIV Vaccines Ira M Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran 241 -- Chapter 13. Health Policy Modeling: Epidemic Control, HIVVaccines, and -- Risky Behavior Sally Blower, Katia Koelle,and John Mills 260 -- Chapter 14. Development and Validation of a Serologic Testing Algorithm for Recent HIV Seroconversion GlenA. Satten, -- Robert S. Janssen, Susan Stramer, and Michael P Busch 290 -- Chapter 15. Issues in Quantitative Evaluation of Epidemiologic Evidence for Temporal Variability of HIV Infectivity Stephen C. Shiboski and Nancy S. -- Padian 305.
000399266 506__ $$aAccess limited to authorized users.
000399266 650_0 $$aAIDS (Disease)$$xPrevention$$vCongresses.
000399266 650_0 $$aAIDS (Disease)$$xPrevention$$xGovernment policy$$xEvaluation$$vCongresses.
000399266 655_7 $$aElectronic books.$$2lcsh
000399266 7001_ $$aKaplan, Edward Harris.
000399266 7001_ $$aBrookmeyer, Ron.
000399266 830_0 $$aYale ISPS series.
000399266 852__ $$bebk
000399266 85640 $$3ProQuest Ebook Central Academic Complete$$uhttps://univsouthin.idm.oclc.org/login?url=http://site.ebrary.com/lib/usiricelib/Doc?id=10210208$$zOnline Access
000399266 909CO $$ooai:library.usi.edu:399266$$pGLOBAL_SET
000399266 980__ $$aEBOOK
000399266 980__ $$aBIB
000399266 982__ $$aEbook
000399266 983__ $$aOnline